Similar articles

• Editorial comment on: Pharmacological approaches to reducing the risk of prostate cancer.

  Orvieto M, Eggener S. Orvieto M, et al. Eur Urol. 2009 May;55(5):1073-4. doi: 10.1016/j.eururo.2009.01.038. Epub 2009 Feb 5. Eur Urol. 2009. PMID: 19200640 No abstract available.
• Pharmacological approaches to reducing the risk of prostate cancer.

  Rittmaster RS, Fleshner NE, Thompson IM. Rittmaster RS, et al. Eur Urol. 2009 May;55(5):1064-73. doi: 10.1016/j.eururo.2009.01.037. Epub 2009 Feb 5. Eur Urol. 2009. PMID: 19200641 Review.
• Chemoprevention of prostate cancer.

  Stephenson AJ, Abouassaly R, Klein EA. Stephenson AJ, et al. Urol Clin North Am. 2010 Feb;37(1):11-21, Table of Contents. doi: 10.1016/j.ucl.2009.11.003. Urol Clin North Am. 2010. PMID: 20152515 Review.
• Prevention of prostate cancer with finasteride.

  Ross RK, Skinner E, Cote RJ. Ross RK, et al. N Engl J Med. 2003 Oct 16;349(16):1569-72; author reply 1569-72. N Engl J Med. 2003. PMID: 14562807 No abstract available.
• Effect of finasteride on risk of prostate cancer: how little we really know.

  Rubin MA, Kantoff PW. Rubin MA, et al. J Cell Biochem. 2004 Feb 15;91(3):478-82. doi: 10.1002/jcb.10787. J Cell Biochem. 2004. PMID: 14755678 Review.